The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5′-End- and DNA 3′-End-Directed RNase H Activities

Similar Items

• Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture
  od: Archer, Richard H., i dr.
  Izdano: (2000)
• Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)
  od: Demeter, L. M., i dr.
  Izdano: (2000)
• ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy
  od: Para, Michael F., i dr.
  Izdano: (1999)
• Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase.
  od: DeStefano, J J, i dr.
  Izdano: (1993)
• Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and RNase H
  od: Marchand, Christophe, i dr.
  Izdano: (2008)